Comparative Analysis of Metformin and Empagliflozin in Male Wistar Rats with Non-Diabetic Chronic Kidney Disease
Abstract
Background: Chronic kidney disease has been identified as one of the greatest challenges faced by global public health. It is very important to highlight that T2DM (Type 2 Diabetes Mellitus) is an important driver of Chronic Kidney Disease, and its number is increasing due to this causative relationship. Objective: To determine the differences in the effectiveness of Metformin and Empagliflozin on kidney function in the different stages of chronic kidney disease development without diabetes in male Wistar rats.Materials and Method: In this experimental study, 54 male Wistar rats were included in this study. The rats were housed under standardized environmental conditions. Metformin and Empagliflozin were fed daily orally by gavage, with dosages determined according to the dosage adjustment principles for kidney failure. Rats were randomly distributed into three groups, including a control group. The study employed serum creatinine levels, as well as creatinine clearance, to ascertain kidney function. The study spread over nine weeks and ended with integrity being approached.Results: Serum creatinine levels showed a decrease in Metformin groups for a duration of 4 and 5 weeks, which is different from the moderate impact of Empagliflozin exposure. Creatinine clearance showed an appreciable increase in the Metformin groups, which is remarkable evidence of its nephroprotective properties. Empagliflozin yet produced less effect.Conclusion: The study reports that the low-dose…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.